Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. / Stensen, Signe; Krogh, Liva L.; Sparre-Ulrich, Alexander H.; Dela, Flemming; Hartmann, Bolette; Vilsbøll, Tina; Holst, Jens J; Rosenkilde, Mette M; Christensen, Mikkel B; Gasbjerg, Lærke S.; Knop, Filip K.

In: Diabetes, Obesity and Metabolism, Vol. 24, No. 9, 2022, p. 1882-1887.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stensen, S, Krogh, LL, Sparre-Ulrich, AH, Dela, F, Hartmann, B, Vilsbøll, T, Holst, JJ, Rosenkilde, MM, Christensen, MB, Gasbjerg, LS & Knop, FK 2022, 'Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity', Diabetes, Obesity and Metabolism, vol. 24, no. 9, pp. 1882-1887. https://doi.org/10.1111/dom.14736

APA

Stensen, S., Krogh, L. L., Sparre-Ulrich, A. H., Dela, F., Hartmann, B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., Christensen, M. B., Gasbjerg, L. S., & Knop, F. K. (2022). Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism, 24(9), 1882-1887. https://doi.org/10.1111/dom.14736

Vancouver

Stensen S, Krogh LL, Sparre-Ulrich AH, Dela F, Hartmann B, Vilsbøll T et al. Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. Diabetes, Obesity and Metabolism. 2022;24(9):1882-1887. https://doi.org/10.1111/dom.14736

Author

Stensen, Signe ; Krogh, Liva L. ; Sparre-Ulrich, Alexander H. ; Dela, Flemming ; Hartmann, Bolette ; Vilsbøll, Tina ; Holst, Jens J ; Rosenkilde, Mette M ; Christensen, Mikkel B ; Gasbjerg, Lærke S. ; Knop, Filip K. / Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity. In: Diabetes, Obesity and Metabolism. 2022 ; Vol. 24, No. 9. pp. 1882-1887.

Bibtex

@article{de62de24acb34249811ec276b8f850dd,
title = "Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity",
abstract = "AIMS: When combined with glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, antagonising the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) reduces body weight in rodent models of obesity. Here, we investigated the acute effects of GIPR antagonism combined with a GLP-1 infusion on determinants of body weight in patients with type 2 diabetes and overweight/obesity.MATERIALS AND METHODS: In a randomised, double-blind, placebo-controlled, crossover design, human synthetic GLP-1(7-36)NH 2 (0.75 pmol/kg/min) was infused together with the selective GIPR antagonist GIP(3-30)NH 2 (1,200 pmol/kg/min) or placebo for 320 minutes on two separate days covering an initial oral liquid mixed meal test and a terminal ad libitum meal. Appetite sensations, resting energy expenditure (REE) and food intake were evaluated, and subcutaneous adipose tissue (SAT) biopsies were analysed for triglyceride content. RESULTS: Ten patients with type 2 diabetes and overweight/obesity (mean±SD; HbA 1c 52±9 mmol/mol (7±1%); BMI 32.5±4.8 kg/m 2 ) were included. Compared to placebo, infusion of the GIPR antagonist GIP(3-30)NH 2 added to a GLP-1 infusion had no effect on appetite sensations, REE, food intake, or SAT triglyceride content during an ad libitum meal. Compared to placebo, GIP(3-30)NH 2 lowered plasma glucagon by -12.4±5.9% (p=0.037), and reduced serum insulin by -32.5±8.0% (p=0.027). CONCLUSIONS: During short term infusion, we found no effect of GIPR antagonism added to GLP-1R agonism on appetite sensations, REE, SAT triglyceride content or food intake in patients with type 2 diabetes and overweight/obesity. This article is protected by copyright. All rights reserved.",
author = "Signe Stensen and Krogh, {Liva L.} and Sparre-Ulrich, {Alexander H.} and Flemming Dela and Bolette Hartmann and Tina Vilsb{\o}ll and Holst, {Jens J} and Rosenkilde, {Mette M} and Christensen, {Mikkel B} and Gasbjerg, {L{\ae}rke S.} and Knop, {Filip K}",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
doi = "10.1111/dom.14736",
language = "English",
volume = "24",
pages = "1882--1887",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Acute concomitant GIP receptor antagonism during GLP-1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

AU - Stensen, Signe

AU - Krogh, Liva L.

AU - Sparre-Ulrich, Alexander H.

AU - Dela, Flemming

AU - Hartmann, Bolette

AU - Vilsbøll, Tina

AU - Holst, Jens J

AU - Rosenkilde, Mette M

AU - Christensen, Mikkel B

AU - Gasbjerg, Lærke S.

AU - Knop, Filip K

N1 - This article is protected by copyright. All rights reserved.

PY - 2022

Y1 - 2022

N2 - AIMS: When combined with glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, antagonising the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) reduces body weight in rodent models of obesity. Here, we investigated the acute effects of GIPR antagonism combined with a GLP-1 infusion on determinants of body weight in patients with type 2 diabetes and overweight/obesity.MATERIALS AND METHODS: In a randomised, double-blind, placebo-controlled, crossover design, human synthetic GLP-1(7-36)NH 2 (0.75 pmol/kg/min) was infused together with the selective GIPR antagonist GIP(3-30)NH 2 (1,200 pmol/kg/min) or placebo for 320 minutes on two separate days covering an initial oral liquid mixed meal test and a terminal ad libitum meal. Appetite sensations, resting energy expenditure (REE) and food intake were evaluated, and subcutaneous adipose tissue (SAT) biopsies were analysed for triglyceride content. RESULTS: Ten patients with type 2 diabetes and overweight/obesity (mean±SD; HbA 1c 52±9 mmol/mol (7±1%); BMI 32.5±4.8 kg/m 2 ) were included. Compared to placebo, infusion of the GIPR antagonist GIP(3-30)NH 2 added to a GLP-1 infusion had no effect on appetite sensations, REE, food intake, or SAT triglyceride content during an ad libitum meal. Compared to placebo, GIP(3-30)NH 2 lowered plasma glucagon by -12.4±5.9% (p=0.037), and reduced serum insulin by -32.5±8.0% (p=0.027). CONCLUSIONS: During short term infusion, we found no effect of GIPR antagonism added to GLP-1R agonism on appetite sensations, REE, SAT triglyceride content or food intake in patients with type 2 diabetes and overweight/obesity. This article is protected by copyright. All rights reserved.

AB - AIMS: When combined with glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, antagonising the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) reduces body weight in rodent models of obesity. Here, we investigated the acute effects of GIPR antagonism combined with a GLP-1 infusion on determinants of body weight in patients with type 2 diabetes and overweight/obesity.MATERIALS AND METHODS: In a randomised, double-blind, placebo-controlled, crossover design, human synthetic GLP-1(7-36)NH 2 (0.75 pmol/kg/min) was infused together with the selective GIPR antagonist GIP(3-30)NH 2 (1,200 pmol/kg/min) or placebo for 320 minutes on two separate days covering an initial oral liquid mixed meal test and a terminal ad libitum meal. Appetite sensations, resting energy expenditure (REE) and food intake were evaluated, and subcutaneous adipose tissue (SAT) biopsies were analysed for triglyceride content. RESULTS: Ten patients with type 2 diabetes and overweight/obesity (mean±SD; HbA 1c 52±9 mmol/mol (7±1%); BMI 32.5±4.8 kg/m 2 ) were included. Compared to placebo, infusion of the GIPR antagonist GIP(3-30)NH 2 added to a GLP-1 infusion had no effect on appetite sensations, REE, food intake, or SAT triglyceride content during an ad libitum meal. Compared to placebo, GIP(3-30)NH 2 lowered plasma glucagon by -12.4±5.9% (p=0.037), and reduced serum insulin by -32.5±8.0% (p=0.027). CONCLUSIONS: During short term infusion, we found no effect of GIPR antagonism added to GLP-1R agonism on appetite sensations, REE, SAT triglyceride content or food intake in patients with type 2 diabetes and overweight/obesity. This article is protected by copyright. All rights reserved.

U2 - 10.1111/dom.14736

DO - 10.1111/dom.14736

M3 - Journal article

C2 - 35491518

VL - 24

SP - 1882

EP - 1887

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 9

ER -

ID: 311121885